Department of Clinical Molecular Biology, Medical University of Bialystok, Poland.
Adv Clin Exp Med. 2023 Sep;32(9):1029-1040. doi: 10.17219/acem/159799.
Ovarian cancer (OC) is a global challenge for modern medicine, ranking 7th for incidence and the 8th most common cause of mortality from cancers in women. Ovarian cancer has a poor prognosis, characterized by high morbidity and mortality, with detection occurring more frequently in advanced stages. Further issues lie within the heterogeneous nature of this pathology, as well as in its ability to develop multidrug resistance. Therefore, there is a burgeoning need to introduce effective screening for the general population, especially in high-risk groups such as individuals with a family history of cancer. Achieving this would be greatly assisted by identifying new biomarkers in order to, in turn, develop targeted therapies for patients. Advances in molecular biology techniques that enable cancer genetic characterization offer hope for personalized medicine. This article reviews the current findings on the biology of OC at the molecular level. Such knowledge may prove to be crucial and constitute a starting point for the development of new options for the early detection, prevention and treatment of OC.
卵巢癌 (OC) 是现代医学面临的全球性挑战，其发病率排名第 7，死亡率在女性癌症中排名第 8。卵巢癌预后不良，其特点是发病率和死亡率高，且更多在晚期才被发现。此外，这种病理学的异质性以及其发展为多药耐药性的能力也是问题所在。因此，迫切需要为普通人群引入有效的筛查，特别是对于有癌症家族史等高危人群。通过识别新的生物标志物来确定治疗靶点，从而为患者提供靶向治疗，将极大地有助于实现这一目标。癌症遗传特征的分子生物学技术的进步为个性化医疗带来了希望。本文综述了 OC 在分子水平上的生物学研究现状。这些知识可能被证明是至关重要的，并为早期发现、预防和治疗 OC 提供新的选择提供了起点。
